<DOC>
	<DOC>NCT02962102</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.</brief_summary>
	<brief_title>Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Age ≥ 18 Admitted to the ICU within 48h prior to enrollment Likely to remain in the ICU (alive) for ≥72h Naso/orogastric tube or ability to swallow High risk of severe AKI Serum total calcium &gt; 9.0 mg/dl or phosphate &gt; 6.0 mg/dL within previous 48h Currently receiving oral calcium supplementation Ingestion of vitamin D3 &gt;1,000 IU/day or any 25hydroxyvitamin D or 1,25dihydroxyvitamin D during the previous 7 days AKI stage 2 or 3 (based on KDIGO serum creatinine and/or urine output criteria) History of transplantation or receiving immunosuppressive medications (not including glucocorticoid steroids at a dose less than or equivalent to prednisone 20 mg/day) Neutropenia in the previous 48h Active primary parathyroid disease, active granulomatous disease, or symptomatic nephrolithiasis in the previous 3 months Receiving cytochrome P450 inhibitors Chronic Kidney Disease stage V or End Stage Renal Disease Hemoglobin &lt; 7 g/dL GI malabsorption Prisoner Pregnancy or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>